Accelerating Research and Development of Next Generation Vaccines against Malaria supports researchers developing highly effective, long-lasting vaccines to protect against malaria and inform other vaccine work.
Funder: National Institutes of Health
Due Dates: February 11, 2027 (Application deadline)
Funding Amounts: $4,000,000 estimated total program funding; no cost sharing or matching required
Summary: Supports research and preclinical development of highly effective, long-lasting malaria vaccines that may inform protection against other mosquito-borne diseases.
Key Information: Clinical trials are not allowed, and applications involving foreign subawards or subcontracts will not be considered for funding.
The National Institutes of Health supports research and/or preclinical development of highly efficacious malaria vaccines through this R61/R33 opportunity. The program seeks to capitalize on recent technological innovations, particularly structure-based immunogen design, improved formulations, and combination vaccines.
Its goal is long-lasting, highly effective protection against malaria, one of the deadliest mosquito-borne diseases. Supported work should advance protection that can save lives and strengthen public health security in the United States. The program also seeks advances that can serve as a model for vaccine development against other mosquito-borne diseases or potentially provide protection against them.